Secondary Research Sample Clauses

Secondary Research. The review of existing information sources to use for analysis and in reference to a specific topic area.
Sample 1Sample 2
AutoNDA by SimpleDocs
Secondary Research. Institution may not (i) use the Biological Samples collected under the Protocol, (ii) collect additional quantities of Biological Samples (i.e. exceeding quantities which the Protocol specifies to be collected), and/or (iii) retain any quantities of Biological Samples not used for purposes of conducting the research specified by the Protocol, for purposes of testing or use in research that is not described in the Protocol, including pharmacokinetic, pharmacogenomics, and 6.4 Sekundární výzkum. Zdravotnické zařízení nesmí (i) použít biologické vzorky odebrané podle protokolu, (ii) odebrat dodatečná množství biologických vzorků (tj. překročit odebírané množství specifikované protokolem) anebo (iii) si ponechat jakákoli množství biologických vzorků nepoužitých pro účely provádění výzkumu specifikovaného protokolem pro účely zkoušení nebo použití ve výzkumu, který není popsán v protokolu, včetně farmakokinetického, farmakogenomického a biomarker testing and research. biomarkerového testování a výzkumu.
Sample 1
Secondary Research. Institution/Principal Investigator may not (i) use the Biological Samples collected under the Protocol, (ii) collect additional quantities of Biological Samples (i.e. exceeding quantities which the Protocol specifies to be collected), and/or (iii) retain any quantities of Biological Samples not used for purposes of conducting the research specified by the Protocol, for purposes of testing or use in research that is not described in the Protocol, including pharmacokinetic, pharmacogenomics, and biomarker testing and research. 7.
Sample 1
Secondary Research. Institution/Principal Investigator may not (i) use the Biological Samples collected under the Protocol, (ii) collect additional quantities of Biological Samples (i.e. exceeding quantities which the Protocol specifies to be collected), and/or (iii) retain any quantities of Biological Samples not used for purposes of conducting the research specified by the Protocol, for purposes of testing or use in research that is not described in the Protocol, including pharmacokinetic, pharmacogenomics, and biomarker testing and research. 6.4 Sekundárny výskum. Inštitúcia/zodpovedný skúšajúci nesmú i) použiť biologické vzorky odobraté podľa tohto protokolu, ii) odoberať dodatočné množstvá biologických vzoriek (t.j. prekročiť množstvá, ktoré protokol špecifikuje na odber), a/alebo iii) ponechať si akékoľvek množstvo biologických vzoriek nepoužitých na účely výskumu podľa protokolu, na účely testovania alebo použitia vo výskume, ktorý nie je opísaný v protokole, vrátane farmakokinetického, farmakogenomického a biomarkerového testovania a výskumu.
Sample 1
Secondary Research. Institution may not (i) use the Biological Samples collected under the Protocol, (ii) collect additional quantities of Biological Samples (i.e. exceeding quantities which the Protocol specifies to be collected), and/or (iii) retain any quantities of Biological Samples not used for purposes of conducting the research specified by the Protocol, for purposes of testing or use in research that is 6.4 Sekundární výzkum. Zdravotnické zařízení nesmí (i) použít biologické vzorky odebrané podle protokolu, (ii) odebrat dodatečná množství biologických vzorků (tj. překročit odebírané množství specifikované protokolem) anebo (iii) si ponechat jakákoli množství biologických vzorků nepoužitých pro účely provádění výzkumu specifikovaného protokolem pro účely zkoušení nebo použití ve výzkumu, který not described in the Protocol, including pharmacokinetic, pharmacogenomics, and biomarker testing and research. není popsán v protokolu, včetně farmakokinetického, farmakogenomického a biomarkerového testování a výzkumu.
Sample 1

Related to Secondary Research

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Research Design The data generated by excavations at the prehistoric site(s) will be used to examine at least three topics: (1) chronology; (2) technology; and (3) subsistence practices. Insights into changing patterns of community organization may also be granted, as may insights into changes in social organization. The data recovered will then be compared to data from other regional sites.

Time is Money Join Law Insider Premium to draft better contracts faster.